In 2014, He received the prestigious James Palmer Award for excellence in drug development (BMS R&D award), especially for his leadership in accelerating the pace of innovation, and his team's accelerated development of HIV-1 Maturation Inhibitors
A new class of antiretroviral drugs, the maturation inhibitors, is now emerging, which target the internal structural precursor protein, Gag, and its function in final assembly of the mature infectious virion.
Bevirimat is a new agent and the first of its kind in a new class of antiretrovirals: the maturation inhibitors. It directly targets the processing of the Gag polyprotein, a late stage in the replicative process of HIV.
Maturation inhibitors: a new therapeutic class targets the virus structure.
There are also other drugs in the integrase and CCR5 inhibitor classes that are in development, and additional promising new classes, such as maturation inhibitors
, are being actively evaluated in clinical trials.
"Bevirimat, our first-generation maturation inhibitor, has shown the potential clinical value of maturation inhibitors," said Graham Allaway, Ph.D., president and chief operating officer of Panacos.
The company intends to file additional INDs for other second-generation maturation inhibitors during 2007 and then select a candidate based partly on human pharmacokinetics to take into multiple dosing human clinical studies.
Food and Drug Administration for the company's second-generation HIV maturation inhibitor, PA-1050040.
And just in case this particular compound turns out not to be safe and effective, the company has other potential maturation inhibitors ready, to take its place.
Both maturation inhibitors and protease inhibitors block viral maturation and cause new virus particles to be non-infectious.
PA-457 is the first in a new class of HIV drugs called Maturation Inhibitors
, which have a mechanism of action that differs from those of approved HIV drugs.
McCallister will be responsible for medical affairs and will spearhead the company's Phase 3 development efforts for bevirimat, the company's lead candidate in a new class of oral HIV therapeutics called maturation inhibitors
, discovered by Panacos scientists and their academic collaborators.